Alercell is an early-stage biopharmaceutical company developing novel therapeutics and oncology diagnostics tests with the core mission of developing and commercializing oncology diagnostic tests to improve diagnostic accuracy and diagnostic speed.
Alercell is also developing a neural interface to activate novel messaging to the DNA of patient with neurodegenerative diseases.
Alercell is proud to introduce two new tests that are both first of their genre.
2. LENA S1® the first lung cancer diagnostic test
based on methylation.